In Re: Zetia (Ezetimibe) Antitrust Litigation

Track this case

Case overview

Case Number:

2:18-md-02836

Court:

Virginia Eastern

Nature of Suit:

Anti-Trust

Multi Party Litigation:

Class Action, Multi-district Litigation

Judge:

Rebecca Beach Smith

Firms

Companies

Sectors & Industries:

October 02, 2019
Par Settlement Gets OK In Zetia Generic Delay Case

A Virginia magistrate judge has recommended approval of a settlement between several drug purchasers and Par Pharmaceuticals in a case alleging the company, along with Merck & Co. Inc. and Glenmark Pharmaceuticals Inc., conspired to delay a generic version of the cholesterol drug Zetia.
August 21, 2019
Pharmacy Retailers Fight Glenmark's Bid To Exit Zetia MDL

Kroger, Walgreens and a handful of other big-name pharmacy operators have told a Virginia federal court that Glenmark Pharmaceuticals should not be able to escape their antitrust suit tied to the cholesterol drug Zetia, because there is past evidence of a conspiracy agreement.
August 16, 2019
Glenmark Wants Out Of Pharmacies' Pay-For-Delay Lawsuits

Glenmark Pharmaceuticals wants out of an antitrust suit tied to the cholesterol drug Zetia, telling a Virginia federal judge that new claims accusing it of working up a three-way conspiracy with two other drug companies to keep generic versions of the medication off the market are "implausible."
August 09, 2019
Zetia Buyers' Pay-For-Delay Lawsuits Will Press On

Merck and Glenmark weren't able to shut down Zetia buyers' pay-for-delay litigation on Friday, though a Virginia federal judge agreed to pare the claims lodged by retailers and end-payors that bought the cholesterol medication.
July 30, 2019
Merck, Glenmark Rip Zetia Buyers' Par Deal As 'Tactical Move'

Adding Par Pharmaceutical to multidistrict litigation alleging an illegal pay-for-delay agreement to keep a generic version of cholesterol drug Zetia off the market was just a ploy, Merck and Glenmark said in separate briefs Monday, arguing therapy buyers shouldn't be able to so easily get their deal with Par approved.
July 12, 2019
Merck Says Zetia Buyers Can't Expand Pay-For-Delay Suit

Merck & Co. Inc. has asked a Virginia federal judge not to expand multidistrict litigation alleging it conspired with Glenmark Pharmaceuticals Inc. to keep cholesterol drug Zetia off the market using a pay-for-delay agreement, saying buyers can't rope in a distributor and seek new wide-ranging damages.
July 02, 2019
Wilson Sonsini Blasts Zetia Buyers' Bid For More Docs

Wilson Sonsini Goodrich & Rosati has assailed a motion to hand over more documents in a multidistrict litigation by purchasers of cholesterol drug Zetia, telling a Virginia federal court it has already provided plaintiffs with 3,600 pages.
May 17, 2019
Zetia Buyers Demand Info On Generics In Pay-For-Delay Suit

Generic-drug maker Zydus needs to cough up details on its generic version of Zetia, buyers of the cholesterol medication told a Virginia federal court, as they contend that information may bolster their pay-for-delay case against Merck and Glenmark.
February 07, 2019
Zetia Pay-For-Delay MDL Should Press On, Magistrate Says

Zetia buyers have sufficiently alleged that Merck & Co. Inc. and Glenmark Pharmaceuticals Inc. kept a generic of the cholesterol medication off the market using a so-called pay-for-delay agreement, a Virginia federal magistrate judge has said.
December 07, 2018
Merck, Glenmark Can't Shake Zetia Pay-For-Delay MDL

Drugmakers Merck & Co Inc. and Glenmark Pharmaceuticals Ltd. lost a bid to kill multidistrict litigation alleging a pay-for-delay scheme involving the cholesterol medication Zetia when a Virginia federal judge on Thursday said an arbitration clause in Merck's contracts with customers improperly waived their statutory rights, making it unenforceable.